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Summary: Insulin, C-peptide and proinsulin were measured in peripheral blood of 11 patients suffering from
different types of hormone-producing pancreatic B-cell tumours. While proinsulin was elevated in 10/11
patients during prolonged fasting, C-peptide and insulin levels were found within the reference ränge in 5/
11 and 3/5 cases respectively. A rapid insulin assay performed during surgery was helpful for localisation and
identification of the respective tumours.
B-Zellpeptide als Kenngrößen zur Diagnostik und Lokalisation von Insulinomen
Zusammenfassung: Insulin, C-Peptid und Proinsulin wurden bei 11 Patienten mit unterschiedlichen Formen
von B-Zelltumoren gemessen. Proinsulin fand sich in 10/11 Patienten, C-Peptid in 5/11 und Insulin in 2/5
Fällen erhöht. Ein intraoperativ durchgeführter Insulinschnelltest erwies sich als hilfreich zur Lokalisation
und Identifikation der entsprechenden Tumoren.
Introduction Materials and Methods
Hypoglycaemia is an ünspecific Symptom of quite Patients with neuroglucopenic Symptoms are subjected to the
different diseases, including hormone-producing B- m™™Z diagnoitic procedure (1): First, a prolonged (5 hours)
- ~ .' -° \ f oral glucose tolerance test is performed to exclude a reactive
cell tumours. Diagnosis of the latter is sometimes hypoglycaemia. The crucial tesl is prolonged fasting, ifpossible,
difficult. Blood glucose measurements during pro- over a period of 72 hours. During this time blood glucose is
loneed fastin^ caldum infmion and other nro- measured at least every four to six hours. For determinationlongea lastmg, caicium miusion ana otner pro
 of ß.^ , peptides^ peripheral blood is drawn at the same time,
vocative and suppressive tests ars used to confirm
 but assays are done only tf the blood sugar concentrations
the diagnosis, but tue existence of an insulinoma is decrease below 500 mg/1. This cut-ofT point is chosen for tvvo
substantiated only by elevated serum concentrations ~« firsl: for the patients it avoids the dangei- of severeJ J
 hypoglycaemic attacks; secondly, m our expenence mam-
of the B-cell peptides insulin, C-peptide and/of pro- tainance of the glucose balance at levels above 500 mg/1 excludes
insulin. Here we report our experience in the di- the existence of a hormone-producing B-cell tumour.
agnosisof 10 hormone-producing B-cell tumours and Insulin was measured äs described (2) using a guinea pig
l case of nesidioblastosis during the last three years. * antiinsulin serurn prepared in our laboratory. C-peptide was
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dctermined by a commercial assay (Behring-Werke, Marburg),
and proinsulin by the procedure described by Heding (3).
Sepharose-coupled insulin antibodies cross-reacting with pro-
insulin were prepared according to 1. c. (3). The anti-C-peptide
serum was the NOVO M 1219 serum, kindly provided by L.
Heding. Three different types of human proinsulin Standards
were used: first, a pancreatic human proinsulin prepared in
1970 at the University of Chicago (4) and kindly donated by
D. Steiner, secondly, human proinsulin material purified in our
laboratory from a human insulinoma; thirdly, a new human
proinsulin highly purified from b-component at the NOVO
Research Institute and kindly provided by V. Kruse. The eval-
uation data for this latter Standard material were published
recently (5). Identical values were obtained when the new Novo
proinsulin Standard was compared with biösynthetic human
proinsulin made by recombinant DNA technology (6). On the
basis of these results, the proinsulin values obtained by use of
the old "Chicago"-standard äs well äs by use of our own
Standard are overestimated by a factor of three. Thus all pro-
insulin concentrations measured with the old Standard are
corrected for this factor.
In some cases B-cell tumoufs are not detectable by other
methods such äs coeliacography, abdominal computerized axial
tomography and sonography. Although in most of these cases
the operating surgeon is able to localize the tumour by pal-
pation, we generally substantiate his finding by insulin meas-
urements in samples obtained during surgery (7). For this
purpose a catheter is inserted into the vena lienalis near the
spieen hilus and carefully pushed forward into the vena portae.
resection
100-
10 50
Prolonged fasting [h] t [h]
Fig. 1. (A-C). Measurement of insulin (A), C-peptide (B) and proinsulin (C) during prolonged fasting.
The numerical order of the patients corresponds to that in the table. Prolonged fasting was interropted when
blood glucose concentration had decreased below 500 mg/1. Note the logaririthmic scaie. Each pöint represents
the mean of two determinations. The shaded areas represent the reference ranges obtained in healthy subjects
after overnight fasting (1). Proinsulin concentrations are corrected for the new purified Standard material
according to 1. c. (5).
Fig. l (D). Proinsulin in serum of Pat. 9 after resection of an insulinoma (single determinations).
The proinsulin concentration measured immediately before removal of the turhöur isJset at 1.
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Then the catheter is retracted and heparinized blood is drawn
at each cm distance. Insulin is measured in tripiicate using a
rapid assay. Briefly the assay procedure is s follows: incubation
of insulin Standards or unknown plasma samples (150 μΐ) for
15 minutes at room temperature with trace amounts of bovine
[125I]insulin (about 10000 counts/min · 50 μΐ) together with a
guinea pig antiinsulin serurn (ΙΟΟ,μΙ) of high titer (final dilution
1:400000). Following incubation, 50 μΐ (50 mg) of human γ-
globulin (Beriglobin®) is added and immediately thereafter the
mixture is precipitated by adding 250 μΐ of a solution of 250
g/l polyethyleneglycol (PEG 6000, Merck, Darmstadt). After
centrifugation in an Eppendorf centrifuge for two minutes, the
supernatant is decanted and the pellet is counted in a Nuclear
Enterprise NE 1600 γ-counter. The assay has a within-run
precision (n = 20) of 18% (CV).
Localisation of the tumour during surgery
An example of the localisation of the tumour by
measurements of insulin during surgery is given in
figure 2. The scheme demonstrates the in situ Situa-
tion together with the insulin concentrations in
plasma samples obtained by catheterization.
Although the operating surgeon (F.S.) had already
palpated two tumours, insulin measurements con-
firmed the presence of two distinct B-cell adenomas.
Results
Figure l demonstrates the diagnostic power of the
three B-cell peptides during prolonged fasting of 10
patients suffering from B-cell adenomas or islet cell
carcinomas. A single determination of C-peptide and
proinsulin in a case of nesidioblastosis is also shown.
Insulin was found to be elevated only in 2 out of 5
patients with insulinomas. In 5/11, C-peptide values
were within or at the upper level of the reference
r nge, while in 6/11 the values were increased 2—5
fold. In 10/11 cases single proinsulin determination
confirmed the diagnosis. In these cases proinsulin
concentrations were elevated 4—50 fold above the
upper level of the reference r nge. In the newborn
suffering from nesidioblastosis greatly elevated pro-
insulin values were found.
Figure l also demonstrates the normalisation of the
proinsulin levels in the ser m of one patient (patient
9) after surgery and resection of the insulinoma. From
the data shown, an apparent in vivo half-life of pro-
insulin of about 120 minutes can be calculated, which
is higher than reported in the literature (2).
Tumour l
Tab.l. Clinical data.
Number
1,
2
3
4
5
6
7
8
9
10
11
Initials
S. T.
S.C.
S.U.
K. U.
N.E.
B.I.
M. A.
A.N.
S.O.
W. D.*
H. U.
Sex
?
?
c?
c?
?
c???
<J??
Age
(years)
38
76
57
47
56
7939
38
47
26
newborn
Tumour
adenoma
adenoma
multiple adenomas
adenoma
adenoma
B-cell carcinoma
2 adenomas
adenoma
adenoma
adenoma
nesidioblastosis
V.portoe Veno lienaUs
2-
Tumour 2
ZOOr
ΊΟΟ
* The patient was diagnosed (Dr. U. Walter) and operated at
the University of W rzburg.
Distance [cm]
Fig. 2. Upper part: schematic localisation of the two adenomas
in situ (patient 7, M.A.).
Lower part: insulin concentrations in plasma samples
obtained by catherization of the v. lienalis. Each point
represents the mean of three determinations.
Discussion
Frequent neuroglucopenic Symptoms usually lead to
the diagnostic search for an insulinoma. Although the
diagnostic procedures have been greatly improved, it
is possible for a patient to suffer for years from a
slowly growing tumour before the correct diagnosis
is substantiated (8). The development of
radioimmunological methods for the determination
of the B-cell peptides, insulin, C-peptide and pro-
insulin made it possible to measure tissue specific
antigens. Pifferences in tissue content, secretion pat-
tern and plasma half-life of these antigens, however,
are to be expected, and they do not have the same
diagnostic value. The value of insulin measurements
is mainly a function of the upper level of the reference
r nge employed, which again is dependent on the
short half-life of insulin and other influences such s
age, sex, body weight etc. The same is true for the
corrected insulin/glucose quotient introduced by
Turner et al. (9). Reports in the literature about the
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diagnostic sensitivity of insulin for the diagnosis of
an insulinoma differ accordingly (8). Before we in-
troduced the C-peptide and proinsulin methods only
about 50% of our insulinoma patients were diag-
nosed immediately from insulin measurements during
prolonged fasting. It was hoped that the C-peptide
assay would further improve the diagnostic proce-
dure. However in the recent report published by
Heding & Kruse (10) on 206 sera from fasting in-
sulinoma patients, elevated C-peptide levels are found
in only 50%, which is consistent with the present
results. The use of both assays, i. e. insulin and C-
peptide, clearly improves the diagnostic evidence.
Probably due to a reduced storage capacity of the
tumour cell (11) and its autonomous secretion, in-
sulinoma patients in general have elevated proinsulin
levels in their serum (2, 3, 10 — 13). In the above
mentioned study (10) only 2/206 sera from in-
sulinoma patients had proinsulin concentrations
within the jreference ränge, which is consistent with
results reported here on a much smaller group of
patients. Thus the diagnostic sensitivity of the pro-
insulin determination is over 90%. Possibly our one
insulinoma patient with normal fasting proinsulin
concentrations is similar to the case recently reported
by Pichl et al. (14), in which hormone secretion by
an insulinoma showed periodicity. With respect to the
diagnostic specificity of the proinsulin determination,
further studies are needed. Hyperproinstilinaemia is
found in patients with thyrotoxicosis (15) and with
cirrhosis (16).
The observed increase in the plasma half-life of pro-
insulin in patient 9 might be oaused by the fact that
hyperproinsulinaemia in such patients is not only a
result of hypersecretion of the autonomous tumour,
but is additionally amplified by decreased peripheral
degradation (17). Intraoperatively, about 20 percent
of the insulinomas are not detected by inspection or
bidigital palpation. Furthermore, in about 12 percent
of cases, multiple adenomas are found (18). Thus
tumour localisation either by preoperative
transhepatic catherisation (19, 20) or intraoperatively
by direct catherisation of the vena lienalis (7, 21) is
absolutely necessary. Since the latter method is less
dangerous for the patient and the rapid insulin assay
needs only about 20 minutes, we prefer the direct
catherisation during sürgefy.
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